<?xml version="1.0" encoding="UTF-8"?>
<p>The triplet regimen of weekly ixazomib‐Rd administered in 28‐day cycles has also been investigated in NDMM (NCT01217957); the overall response rate (ORR) was high (92%), with 58% of patients achieving at least a very good partial response (VGPR). Responses deepened with an increasing number of treatment cycles, and the combination was well tolerated (Kumar 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0029" ref-type="ref">2014b</xref>). Data from this study also showed the feasibility of long‐term maintenance treatment with single‐agent ixazomib (Kumar 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0030" ref-type="ref">2014c</xref>). A parallel study has investigated ixazomib‐Rd in NDMM patients but using a twice‐weekly ixazomib dosing schedule; here, we report the findings from this study (NCT01383928) after a median follow‐up of almost 4 years.
</p>
